Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Syros Pharmaceuticals price target raised to $20 from $17 at Roth Capital » 16:48
10/26/20
10/26
16:48
10/26/20
16:48
SYRS

Syros Pharmaceuticals

$6.82 /

-0.73 (-9.67%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah raised the firm's price target on Syros Pharmaceuticals to $20 from $17 and keeps a Buy rating on the shares. The analyst cites the company's "strong" clinical point-of-care data presented for its oral CDK7 inhibitor SY-5609. Jallah is adding SY-5609 to her model while noting the "encouraging" pharmacokinetic and safety profile of the drug, which she sees as supporting "QD dosing and clinically meaningful exposure levels" while offering "early signs of disease control".

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$6.82 /

-0.73 (-9.67%)

SYRS Syros Pharmaceuticals
$6.82 /

-0.73 (-9.67%)

09/22/20 Alliance Global Partners
Syros Pharmaceuticals initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
08/06/20 JMP Securities
Syros Pharmaceuticals price target raised to $20 from $16 at JMP Securities
08/06/20 Piper Sandler
Syros Pharmaceuticals price target raised to $18 from $14 at Piper Sandler
SYRS Syros Pharmaceuticals
$6.82 /

-0.73 (-9.67%)

Sunday
Hot Stocks
Syros presents initial data from Phase 1 trial of SY-5609 » 15:34
10/25/20
10/25
15:34
10/25/20
15:34
SYRS

Syros Pharmaceuticals

$7.55 /

+0.135 (+1.82%)

Syros Pharmaceuticals…

Syros Pharmaceuticals announced initial safety, pharmacokinetics and pharmacodynamics data from the ongoing dose-escalation portion of its Phase 1 clinical trial of SY-5609 in patients with select solid tumors. SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 inhibitor. These early data demonstrate proof of mechanism in patients with advanced solid tumors and establish a maximum tolerated dose for continuous daily dosing. The data was presented in a poster session at the 32nd EORTC-NCI-AACR Symposium. The study also includes a cohort evaluating SY-5609 in combination with fulvestrant in CDK4/6 inhibitor-resistant HR-positive breast cancer patients. As of August 21, 17 patients had been enrolled in the trial and were eligible for safety, PK and PD analysis. Patients were either treated with continuous daily dosing of single-agent SY-5609 at 1, 3, 4 or 5 mg, or for three weeks on and one week off at 3 mg in combination with fulvestrant. The median age of the patients enrolled in the study was 64. Patients were heavily pretreated with a median of four prior therapies. The MTD for continuous daily dosing was achieved at 3 mg. The data showed that SY-5609 demonstrated dose-dependent increases in POLR2A mRNA expression, a PD marker being used in the trial to measure CDK7 biological activity. Notably, increases in POLR2A in patients treated at 3 mg daily reached levels associated with tumor regressions in preclinical models, as well as with levels of CDK7 target engagement at which a clinical response and apoptosis were observed in a trial of patients treated with a first-generation IV CDK7 inhibitor. SY-5609 demonstrated approximately dose-proportional PK as both a single agent and in combination, minimal accumulation with repeat dosing, and a steady state half-life compatible with once-daily dosing. The majority of adverse events reported with SY-5609 as a single agent were low grade. The most common AEs were nausea, diarrhea, fatigue, platelet count decrease, and vomiting. The safety profile of SY-5609 in combination with fulvestrant was consistent with that of single-agent SY-5609. Five of the 13 patients treated with single-agent SY-5609 were response evaluable, and of those, three achieved stable disease and two had progressive disease; one of the four patients treated in the combination cohort was response evaluable and had progressive disease. The Phase 1 trial continues to actively enroll patients with select solid tumors, including the recently expanded single-agent cohort in lung cancer patients and combination cohort in breast cancer patients, to further evaluate the 3 mg daily dose in focused patient populations. The trial has also been opened to patients with advanced pancreatic cancer, another tumor type that has demonstrated sensitivity to SY-5609 in preclinical models. Additional cohorts are evaluating alternate regimens, supported by preclinical data showing that intermittent regimens of SY-5609 induced tumor regressions. Syros expects to report additional dose-escalation data, including clinical activity data, in mid-2021.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$7.55 /

+0.135 (+1.82%)

SYRS Syros Pharmaceuticals
$7.55 /

+0.135 (+1.82%)

09/22/20 Alliance Global Partners
Syros Pharmaceuticals initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
08/06/20 JMP Securities
Syros Pharmaceuticals price target raised to $20 from $16 at JMP Securities
08/06/20 Piper Sandler
Syros Pharmaceuticals price target raised to $18 from $14 at Piper Sandler
SYRS Syros Pharmaceuticals
$7.55 /

+0.135 (+1.82%)

Over a week ago
Conference/Events
Syros Pharmaceuticals participates in a webinar hosted by Roth Capital » 11:25
09/30/20
09/30
11:25
09/30/20
11:25
SYRS

Syros Pharmaceuticals

$9.03 /

-0.53 (-5.54%)

Roth Capital Biotech…

Roth Capital Biotech Analyst Jallah holds a webinar on September 30 at 12 pm.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$9.03 /

-0.53 (-5.54%)

SYRS Syros Pharmaceuticals
$9.03 /

-0.53 (-5.54%)

09/22/20 Alliance Global Partners
Syros Pharmaceuticals initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
08/06/20 JMP Securities
Syros Pharmaceuticals price target raised to $20 from $16 at JMP Securities
08/06/20 Piper Sandler
Syros Pharmaceuticals price target raised to $18 from $14 at Piper Sandler
SYRS Syros Pharmaceuticals
$9.03 /

-0.53 (-5.54%)

Conference/Events
Syros Pharmaceuticals participates in a webinar hosted by Roth Capital » 04:55
09/30/20
09/30
04:55
09/30/20
04:55
SYRS

Syros Pharmaceuticals

$9.55 /

+0.21 (+2.25%)

Roth Capital Biotech…

Roth Capital Biotech Analyst Jallah holds a webinar on September 30 at 12 pm.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$9.55 /

+0.21 (+2.25%)

SYRS Syros Pharmaceuticals
$9.55 /

+0.21 (+2.25%)

09/22/20 Alliance Global Partners
Syros Pharmaceuticals initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
08/06/20 JMP Securities
Syros Pharmaceuticals price target raised to $20 from $16 at JMP Securities
08/06/20 Piper Sandler
Syros Pharmaceuticals price target raised to $18 from $14 at Piper Sandler
SYRS Syros Pharmaceuticals
$9.55 /

+0.21 (+2.25%)

Conference/Events
Syros Pharmaceuticals participates in a webinar hosted by Roth Capital » 16:06
09/29/20
09/29
16:06
09/29/20
16:06
SYRS

Syros Pharmaceuticals

$9.63 /

+0.29 (+3.10%)

Roth Capital Biotech…

Roth Capital Biotech Analyst Jallah holds a webinar on September 30 at 12 pm.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$9.63 /

+0.29 (+3.10%)

SYRS Syros Pharmaceuticals
$9.63 /

+0.29 (+3.10%)

09/22/20 Alliance Global Partners
Syros Pharmaceuticals initiated with a Buy at Alliance Global Partners
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
08/06/20 JMP Securities
Syros Pharmaceuticals price target raised to $20 from $16 at JMP Securities
08/06/20 Piper Sandler
Syros Pharmaceuticals price target raised to $18 from $14 at Piper Sandler
SYRS Syros Pharmaceuticals
$9.63 /

+0.29 (+3.10%)

Over a month ago
Initiation
Syros Pharmaceuticals initiated with a Buy at Alliance Global Partners » 07:07
09/22/20
09/22
07:07
09/22/20
07:07
SYRS

Syros Pharmaceuticals

$10.10 /

+0.11 (+1.10%)

Alliance Global Partners…

Alliance Global Partners analyst Matt Cross initiated coverage of Syros Pharmaceuticals with a Buy rating and $18 price target. The company has an internal discovery platform focused on transcriptional modulators of genes implicated in cancer and rare diseases that has attracted the attention of well-known players and also boosts an "extensive pipeline" for clinical development, Cross tells investors in a research note.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$10.10 /

+0.11 (+1.10%)

SYRS Syros Pharmaceuticals
$10.10 /

+0.11 (+1.10%)

09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
08/06/20 JMP Securities
Syros Pharmaceuticals price target raised to $20 from $16 at JMP Securities
08/06/20 Piper Sandler
Syros Pharmaceuticals price target raised to $18 from $14 at Piper Sandler
05/29/20 Roth Capital
Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital
SYRS Syros Pharmaceuticals
$10.10 /

+0.11 (+1.10%)

Recommendations
Piper Sandler lays out next potential takeover targets in oncology » 04:57
09/18/20
09/18
04:57
09/18/20
04:57
ALLO

Allogene Therapeutics

$37.14 /

+0.93 (+2.57%)

, GILD

Gilead

$65.02 /

-0.62 (-0.94%)

, IMMU

Acquired by GILD

$85.31 /

-0.09 (-0.11%)

, ALXO

ALX Oncology

$38.43 /

-1.295 (-3.26%)

, APTO

Aptose Biosciences

$5.88 /

-0.065 (-1.09%)

, BPMC

Blueprint Medicines

$78.20 /

+2.23 (+2.94%)

, CLVS

Clovis

$7.48 /

-0.23 (-2.98%)

, DCPH

Deciphera

$52.58 /

+0.91 (+1.76%)

, FATE

Fate Therapeutics

$36.91 /

-0.02 (-0.05%)

, IGMS

IGM Biosciences

$71.20 /

+2.715 (+3.96%)

, IMGN

ImmunoGen

$4.09 /

-0.035 (-0.85%)

, INCY

Incyte

$90.32 /

+0.39 (+0.43%)

, IOVA

Iovance Biotherapeutics

$35.64 /

-0.65 (-1.79%)

, ITOS

iTeos Therapeutics

$28.91 /

+ (+0.00%)

, KURA

Kura Oncology

$29.53 /

+0.44 (+1.51%)

, MRTX

Mirati Therapeutics

$161.86 /

-0.89 (-0.55%)

, SGEN

Seagen

$175.77 /

-0.995 (-0.56%)

, STRO

Sutro Biopharma

$11.07 /

+0.03 (+0.27%)

, SYRS

Syros Pharmaceuticals

$9.52 /

-0.6 (-5.93%)

, TCRR

TCR2 Therapeutics

$19.23 /

-0.04 (-0.21%)

, XNCR

Xencor

$42.12 /

+0.58 (+1.40%)

Piper Sandler analysts…

Piper Sandler analysts highlighted what they believe are the next potential buyout targets in oncology following Gilead's (GILD) $21B purchase of Immunomedics (IMMU). Demand for high quality oncology assets remains high, says Piper, who notes the list covers companies with assets "that are both largely de-risked and target high value indications." The list includes Allogene Therapeutics (ALLO), ALX Oncology (ALXO), Aptose Biosciences (APTO), Blueprint Medicines (BPMC), Clovis (CLVS), Deciphera (DCPH), Fate Therapeutics (FATE), IGM Biosciences (IGMS), ImmunoGen (IMGN), Incyte (INCY), Iovance Biotherapeutics (IOVA), iTeos Therapeutics (ITOS), Kura Oncology (KURA), Mirati Therapeutics (MRTX), Seattle Genetics (SGEN), Sutro Biopharma (STRO), Syros Pharmaceuticals (SYRS), TCR2 Therapeutics (TCRR) and Xencor (XNCR).

ShowHide Related Items >><<
XNCR Xencor
$42.12 /

+0.58 (+1.40%)

TCRR TCR2 Therapeutics
$19.23 /

-0.04 (-0.21%)

SYRS Syros Pharmaceuticals
$9.52 /

-0.6 (-5.93%)

STRO Sutro Biopharma
$11.07 /

+0.03 (+0.27%)

SGEN Seagen
$175.77 /

-0.995 (-0.56%)

MRTX Mirati Therapeutics
$161.86 /

-0.89 (-0.55%)

KURA Kura Oncology
$29.53 /

+0.44 (+1.51%)

IOVA Iovance Biotherapeutics
$35.64 /

-0.65 (-1.79%)

INCY Incyte
$90.32 /

+0.39 (+0.43%)

IMMU Acquired by GILD
$85.31 /

-0.09 (-0.11%)

IMGN ImmunoGen
$4.09 /

-0.035 (-0.85%)

IGMS IGM Biosciences
$71.20 /

+2.715 (+3.96%)

GILD Gilead
$65.02 /

-0.62 (-0.94%)

FATE Fate Therapeutics
$36.91 /

-0.02 (-0.05%)

DCPH Deciphera
$52.58 /

+0.91 (+1.76%)

CLVS Clovis
$7.48 /

-0.23 (-2.98%)

BPMC Blueprint Medicines
$78.20 /

+2.23 (+2.94%)

APTO Aptose Biosciences
$5.88 /

-0.065 (-1.09%)

ALXO ALX Oncology
$38.43 /

-1.295 (-3.26%)

ALLO Allogene Therapeutics
$37.14 /

+0.93 (+2.57%)

ALLO Allogene Therapeutics
$37.14 /

+0.93 (+2.57%)

06/08/20 Truist
Allogene Therapeutics price target raised to $50 from $32 at SunTrust
06/01/20
Fly Intel: Top five analyst downgrades
06/01/20 Oppenheimer
Allogene Therapeutics price target raised to $55 from $50 at Oppenheimer
06/01/20 Raymond James
Allogene Therapeutics downgraded to Market Perform from Outperform at Raymond James
GILD Gilead
$65.02 /

-0.62 (-0.94%)

09/15/20 Maxim
Gilead upgraded to Buy at Maxim following Immunomedics deal
09/15/20 Maxim
Gilead upgraded to Buy from Hold at Maxim
09/15/20 RBC Capital
Gilead price target lowered to $82 from $84 at RBC Capital
09/15/20 Jefferies
Immunomedics downgraded to Hold from Buy at Jefferies
IMMU Acquired by GILD
$85.31 /

-0.09 (-0.11%)

09/17/20 Piper Sandler
Novocure price target raised to $125 from $89 at Piper Sandler
09/15/20
Fly Intel: Top analyst downgrades
09/15/20 Guggenheim
Immunomedics downgraded to Neutral from Buy at Guggenheim
ALXO ALX Oncology
$38.43 /

-1.295 (-3.26%)

08/27/20 Piper Sandler
ALX Oncology on track for catalyst-rich 12 months, says Piper Sandler
08/11/20 Cantor Fitzgerald
ALX Oncology initiated with an Overweight at Cantor Fitzgerald
08/11/20 Cantor Fitzgerald
ALX Oncology initiated with an Overweight at Cantor Fitzgerald
08/11/20 Jefferies
ALX Oncology initiated with a Buy at Jefferies
APTO Aptose Biosciences
$5.88 /

-0.065 (-1.09%)

08/04/20 Piper Sandler
Piper Sandler likes setup for Aptose Biosciences into ASH meeting
06/12/20 Piper Sandler
Aptose Biosciences' EHA update 'incrementally positive,' says Piper Sandler
06/12/20 JonesTrading
JonesTrading optimistic about potential of Aptose Biosciences' CG-806
02/20/20 Maxim
Aptose Biosciences initiated with a Buy at Maxim
BPMC Blueprint Medicines
$78.20 /

+2.23 (+2.94%)

09/07/20 Piper Sandler
Early approval of Blueprint's Gavreto 'a nice surprise,' says Piper Sandler
07/15/20 Deutsche Bank
Blueprint Medicines price target raised to $95 from $85 at Deutsche Bank
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
CLVS Clovis
$7.48 /

-0.23 (-2.98%)

09/17/20 Piper Sandler
Clovis early data show 'consistent' safety profile, says Piper Sandler
05/22/20 H.C. Wainwright
Clovis price target lowered to $29 from $33 at H.C. Wainwright
05/18/20 H.C. Wainwright
Clovis price target raised to $33 from $29 at H.C. Wainwright
05/06/20 H.C. Wainwright
Clovis price target raised to $29 from $27 at H.C. Wainwright
DCPH Deciphera
$52.58 /

+0.91 (+1.76%)

09/17/20 Piper Sandler
Piper says Deciphera update 'another positive' for rebastinib program
09/14/20 JPMorgan
Deciphera resumed with a Neutral at JPMorgan
08/04/20 Piper Sandler
Piper Sandler remain buyers of Deciphera following 'massive' Qinlock beat
07/07/20 Piper Sandler
Deciphera estimates raised on 'exceedingly bullish' survey at Piper Sandler
FATE Fate Therapeutics
$36.91 /

-0.02 (-0.05%)

08/13/20 Cantor Fitzgerald
Fate Therapeutics price target raised to $40 from $32 at Cantor Fitzgerald
06/10/20 Oppenheimer
Fate Therapeutics price target raised to $40 from $34 at Oppenheimer
06/09/20 Piper Sandler
Fate Therapeutics price target lowered to $59 from $63 at Piper Sandler
05/13/20
Fly Intel: Top five analyst initiations
IGMS IGM Biosciences
$71.20 /

+2.715 (+3.96%)

09/14/20 Jefferies
Inhibrx initiated with a Buy at Jefferies
09/09/20 Jefferies
ASH data could prompt 40% rise, or 70% drop, for IGM Biosciences, says Jefferies
07/17/20
Fly Intel: Top five analyst initiations
07/17/20 Baird
Dfferentiated platform at IGM Biosciences, Baird starts at Outperform
IMGN ImmunoGen
$4.09 /

-0.035 (-0.85%)

05/04/20 H.C. Wainwright
ImmunoGen shares offer 'compelling entry point,' says H.C. Wainwright
12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
INCY Incyte
$90.32 /

+0.39 (+0.43%)

09/14/20 Mizuho
Oncology 'fertile ground for M&A activity,' says Mizuho
08/05/20 Mizuho
Incyte price target raised to $95 from $79 at Mizuho
08/03/20 Deutsche Bank
MorphoSys FDA approval in line with expectations, says Deutsche Bank
08/03/20 Piper Sandler
Monjuvi U.S. launch a solid long-term contributor for Incyte, says Piper Sandler
IOVA Iovance Biotherapeutics
$35.64 /

-0.65 (-1.79%)

09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
08/07/20 Chardan
Iovance Biotherapeutics price target raised to $53 from $44 at Chardan
05/29/20 Piper Sandler
Piper says Iovance data for lifileucel continue to 'mature favorably'
ITOS iTeos Therapeutics
$28.91 /

+ (+0.00%)

09/01/20 Piper Sandler
iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
08/18/20 SVB Leerink
SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
08/18/20 JPMorgan
iTeos Therapeutics initiated with an Overweight at JPMorgan
08/18/20 Wedbush
Wedbush bullish on iTeos Therapeutics, initiates with an Outperform
KURA Kura Oncology
$29.53 /

+0.44 (+1.51%)

08/31/20 Barclays
Kura Oncology price target raised to $32 from $24 at Barclays
07/07/20 Credit Suisse
Kura Oncology initiated with an Outperform at Credit Suisse
05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
MRTX Mirati Therapeutics
$161.86 /

-0.89 (-0.55%)

09/17/20 H.C. Wainwright
Mirati Therapeutics price target raised to $185 from $163 at H.C. Wainwright
08/10/20 Oppenheimer
Mirati Therapeutics price target raised to $133 from $105 at Oppenheimer
08/07/20 Barclays
Mirati Therapeutics price target raised to $143 from $123 at Barclays
05/01/20
Fly Intel: Top five analyst upgrades
SGEN Seagen
$175.77 /

-0.995 (-0.56%)

09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
09/15/20 RBC Capital
Seattle Genetics price target raised to $191 from $175 at RBC Capital
09/14/20 RBC Capital
Seattle Genetics price target raised to $191 from $175 at RBC Capital
09/14/20 Piper Sandler
Seattle Genetics price target raised to $172 from $165 at Piper Sandler
STRO Sutro Biopharma
$11.07 /

+0.03 (+0.27%)

09/02/20 Jefferies
Sutro Biopharma initiated with a Buy at Jefferies
07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
05/17/20 Piper Sandler
Sutro Biopharma price target lowered to $20 from $23 at Piper Sandler
01/13/20 Truist
Sutro Biopharma initiated with a Buy at SunTrust
SYRS Syros Pharmaceuticals
$9.52 /

-0.6 (-5.93%)

08/06/20 JMP Securities
Syros Pharmaceuticals price target raised to $20 from $16 at JMP Securities
08/06/20 Piper Sandler
Syros Pharmaceuticals price target raised to $18 from $14 at Piper Sandler
05/29/20 Roth Capital
Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital
05/29/20 Piper Sandler
Syros price target raised to $14 after ASCO update at Piper Sandler
TCRR TCR2 Therapeutics
$19.23 /

-0.04 (-0.21%)

08/21/20
Fly Intel: Top five analyst initiations
08/21/20 Mizuho
Mizuho starts TCR2 Therapeutics with Buy rating, $33 price target
08/20/20 Mizuho
TCR2 Therapeutics initiated with a Buy at Mizuho
08/13/20 Truist
Truist starts TCR2 Therapeutics at Buy with $40 price target
XNCR Xencor
$42.12 /

+0.58 (+1.40%)

07/08/20 Piper Sandler
Xencor, Atreca deal offers synergies for XmAb design, says Piper Sandler
06/22/20 Piper Sandler
Xencor's '2+1' biospecific antibodies ideal for solid tumors, says Piper Sandler
05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
XNCR Xencor
$42.12 /

+0.58 (+1.40%)

TCRR TCR2 Therapeutics
$19.23 /

-0.04 (-0.21%)

SYRS Syros Pharmaceuticals
$9.52 /

-0.6 (-5.93%)

STRO Sutro Biopharma
$11.07 /

+0.03 (+0.27%)

SGEN Seagen
$175.77 /

-0.995 (-0.56%)

MRTX Mirati Therapeutics
$161.86 /

-0.89 (-0.55%)

KURA Kura Oncology
$29.53 /

+0.44 (+1.51%)

ITOS iTeos Therapeutics
$28.91 /

+ (+0.00%)

IOVA Iovance Biotherapeutics
$35.64 /

-0.65 (-1.79%)

INCY Incyte
$90.32 /

+0.39 (+0.43%)

IMMU Acquired by GILD
$85.31 /

-0.09 (-0.11%)

IMGN ImmunoGen
$4.09 /

-0.035 (-0.85%)

IGMS IGM Biosciences
$71.20 /

+2.715 (+3.96%)

GILD Gilead
$65.02 /

-0.62 (-0.94%)

FATE Fate Therapeutics
$36.91 /

-0.02 (-0.05%)

DCPH Deciphera
$52.58 /

+0.91 (+1.76%)

CLVS Clovis
$7.48 /

-0.23 (-2.98%)

BPMC Blueprint Medicines
$78.20 /

+2.23 (+2.94%)

APTO Aptose Biosciences
$5.88 /

-0.065 (-1.09%)

ALXO ALX Oncology
$38.43 /

-1.295 (-3.26%)

ALLO Allogene Therapeutics
$37.14 /

+0.93 (+2.57%)

  • 29
    Jul
  • 24
    Jul
  • 16
    Jul
  • 17
    Jul
  • 09
    Jun
  • 02
    Jun
  • 29
    May
  • 19
    May
  • 12
    May
  • 06
    May
  • 29
    Apr
  • 14
    Feb
  • 21
    Jan
  • 23
    Jan
  • 10
    Jan
  • 17
    Dec
  • 05
    Dec
MRTX Mirati Therapeutics
$161.86 /

-0.89 (-0.55%)

IOVA Iovance Biotherapeutics
$35.64 /

-0.65 (-1.79%)

IMMU Acquired by GILD
$85.31 /

-0.09 (-0.11%)

GILD Gilead
$65.02 /

-0.62 (-0.94%)

XNCR Xencor
$42.12 /

+0.58 (+1.40%)

STRO Sutro Biopharma
$11.07 /

+0.03 (+0.27%)

SGEN Seagen
$175.77 /

-0.995 (-0.56%)

ITOS iTeos Therapeutics
$28.91 /

+ (+0.00%)

IOVA Iovance Biotherapeutics
$35.64 /

-0.65 (-1.79%)

INCY Incyte
$90.32 /

+0.39 (+0.43%)

IGMS IGM Biosciences
$71.20 /

+2.715 (+3.96%)

GILD Gilead
$65.02 /

-0.62 (-0.94%)

FATE Fate Therapeutics
$36.91 /

-0.02 (-0.05%)

CLVS Clovis
$7.48 /

-0.23 (-2.98%)

BPMC Blueprint Medicines
$78.20 /

+2.23 (+2.94%)

APTO Aptose Biosciences
$5.88 /

-0.065 (-1.09%)

ALXO ALX Oncology
$38.43 /

-1.295 (-3.26%)

ALLO Allogene Therapeutics
$37.14 /

+0.93 (+2.57%)

IOVA Iovance Biotherapeutics
$35.64 /

-0.65 (-1.79%)

INCY Incyte
$90.32 /

+0.39 (+0.43%)

IMMU Acquired by GILD
$85.31 /

-0.09 (-0.11%)

IGMS IGM Biosciences
$71.20 /

+2.715 (+3.96%)

GILD Gilead
$65.02 /

-0.62 (-0.94%)

CLVS Clovis
$7.48 /

-0.23 (-2.98%)

Recommendations
Syros Pharmaceuticals price target raised to $20 from $16 at JMP Securities » 14:00
08/06/20
08/06
14:00
08/06/20
14:00
SYRS

Syros Pharmaceuticals

$11.83 /

+0.525 (+4.64%)

JMP Securities analyst…

JMP Securities analyst Jason Butler raised the firm's price target on Syros Pharmaceuticals to $20 from $16 and reiterates an Outperform rating on the shares following the company's Q2 results. Clinical progress remains on track for key readouts in Q4, Butler tells investors in a research note. Important clinical catalysts for both Syros' lead oral candidates in oncology, SY-1425 and SY-5609, remain anticipated in Q4, says the analyst, who views the readouts as "key potential inflection points" for the shares.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$11.83 /

+0.525 (+4.64%)

SYRS Syros Pharmaceuticals
$11.83 /

+0.525 (+4.64%)

08/06/20 Piper Sandler
Syros Pharmaceuticals price target raised to $18 from $14 at Piper Sandler
05/29/20 Roth Capital
Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital
05/29/20 Piper Sandler
Syros price target raised to $14 after ASCO update at Piper Sandler
04/23/20 JonesTrading
Syros Pharmaceuticals initiated with a Buy at JonesTrading
SYRS Syros Pharmaceuticals
$11.83 /

+0.525 (+4.64%)

Recommendations
Syros Pharmaceuticals price target raised to $18 from $14 at Piper Sandler » 12:19
08/06/20
08/06
12:19
08/06/20
12:19
SYRS

Syros Pharmaceuticals

$11.62 /

+0.315 (+2.79%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Syros Pharmaceuticals to $18 from $14 and keeps an Overweight rating on the shares after the company reported Q2 results. Tenthoff noted that the company ended Q2 with cash of $109M and remains on-track to report data for SY-5609 and SY-1425 in Q4. The analyst added that the phase II study of SY-1425 plus azacitidine has completed enrollment and will report data in Q4, and that he also anticipates updated Phase II SY-1425 and azacitidine data for newly diagnosed acute myeloid leukemia patients.

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$11.62 /

+0.315 (+2.79%)

SYRS Syros Pharmaceuticals
$11.62 /

+0.315 (+2.79%)

05/29/20 Roth Capital
Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital
05/29/20 Piper Sandler
Syros price target raised to $14 after ASCO update at Piper Sandler
04/23/20 JonesTrading
Syros Pharmaceuticals initiated with a Buy at JonesTrading
03/06/20 H.C. Wainwright
Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright
SYRS Syros Pharmaceuticals
$11.62 /

+0.315 (+2.79%)

Earnings
Syros Pharmaceuticals reports Q2 EPS (38c), consensus (40c) » 07:55
08/06/20
08/06
07:55
08/06/20
07:55
SYRS

Syros Pharmaceuticals

$11.31 /

+0.465 (+4.29%)

Reports Q2 revenue $3.2M,…

Reports Q2 revenue $3.2M, consensus $1.9M. "Despite the unforeseen challenges of recent months, our team at Syros has shown remarkable resiliency, continuing to execute with excellence as we advance our product candidates toward key data readouts and progress earlier-stage research," said Nancy Simonian, M.D., CEO of Syros. "We completed enrollment in our Phase 2 trial of SY-1425, opened a new combination cohort in treatment-resistant breast cancer patients in our Phase 1 trial of SY-5609, and presented new preclinical data on SY-5609 in colorectal cancer that further highlights CDK7 inhibition as a potentially transformative targeted approach for difficult-to-treat cancers. Looking ahead, the second half of 2020 promises to be an exciting time for Syros, with planned data readouts for SY-1425 in two RARA-positive AML patient populations and the first clinical data from the Phase 1 trial of SY-5609 in select solid tumor patients. These data will provide valuable insights that will help inform next steps and, hopefully, bring us closer to our vision of building an enduring company with medicines that provide a profound benefit for patients."

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$11.31 /

+0.465 (+4.29%)

SYRS Syros Pharmaceuticals
$11.31 /

+0.465 (+4.29%)

05/29/20 Roth Capital
Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital
05/29/20 Piper Sandler
Syros price target raised to $14 after ASCO update at Piper Sandler
04/23/20 JonesTrading
Syros Pharmaceuticals initiated with a Buy at JonesTrading
03/06/20 H.C. Wainwright
Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright
SYRS Syros Pharmaceuticals
$11.31 /

+0.465 (+4.29%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.